vorinostat + lapatinib

This combination therapy consists of vorinostat, a pan-histone deacetylase (HDAC) inhibitor, and lapatinib, a dual tyrosine kinase inhibitor targeting EGFR (HER1) and HER2. Developed in this specific context by the University of Maryland, Baltimore, the regimen was evaluated in a Phase I/II clinical trial (GCC 0845) for patients with advanced solid tumors and HER2-positive metastatic breast cancer. Vorinostat works by inducing cell cycle arrest and apoptosis through chromatin remodeling, while lapatinib inhibits the intracellular kinase domains of HER1 and HER2, blocking downstream signaling pathways. Preclinical evidence suggested that the combination synergistically targets cancer stem cells and reduces metastasis more effectively than monotherapy.

Brand names

ZolinzaTykerbTyverb

Other names

suberoylanilide hydroxamic acidSAHAlapatinib ditosylate